{"analyses":[{"ciLowerLimit":"0.142","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.653","groupDescription":"Odds ratio: CZP/PBO and p-value were calculated using logistic regression with factors for treatment, region and MRI/CRP classification.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"=0.247","paramType":"Odds Ratio (OR)","paramValue":"0.484","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The number of subjects with AU or new AU flares during the study treatment period.","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"Throughout the study conduct (up to Week 52)","title":"Number of Subjects With Anterior Uveitis (AU) or New AU Flares Through Week 52","type":"SECONDARY","unitOfMeasure":"Participants"}